Full Press Release Details
Disclosure of an inside information
acc. to Article 17 MAR of the Regulation (EU) No 596/2014
Ad hoc: Evotec SE and Sandoz AG planning
potential sale of Just - Evotec Biologics Toulouse site
Hamburg, Germany - Evotec SE (Frankfurt
Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces the signing of a non-binding
agreement with Sandoz AG (SIX:SDZ/OTCQX:SDZNY) regarding the potential sale of Just - Evotec Biologics EU in Toulouse, France,
for a consideration of about US$ 300 m in cash. In addition, the planned transaction terms include further technology related consideration,
future development revenues, milestones and product royalties.
Under the proposed terms of the transaction,
Sandoz would assume full ownership of the Just - Evotec Biologics Toulouse site, while Evotec would retain short-, mid-, and long-term
economic upside through revenue, milestones and royalty optionality.
The planned deal would immediately improve
Evotec's revenue mix, profit margins, and capital efficiency. Closing of the planned transaction remains subject to the completion
of the relevant information and consultation processes with its employees and their representatives, final contractual agreements and
to meeting regulatory requirements.
- End of the ad hoc release -
Contact: Volker Braun, EVP Head of
Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0) 151
1940 5058 (m), volker.braun@evotec.com